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Multidrug resistance (MDR) is an extremely complexed phenomenon in tumor chemotherapy and is one of the major obstacles for 
successful treatment. Discovery of RNA interference (RNAi) offers a new strategy with great potential to reverse MDR. Specific 
genes, which contribute to the emerging of MDR, can be silenced by RNAi. However, many natural barriers have to be overcome 
for efficient and safe delivery of siRNA. In recent years, the various kinds of nanocarriers, such as liposomes, cationic polymers, 
and inorganic materials, have been developed to deliver siRNA and show good results in reversing MDR. This review mainly 
summarizes the barriers in siRNA delivery and recent progress in designing nanotechnology-based siRNA delivery systems to 
overcome tumor MDR. 
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Malignant tumor is one of the major diseases seriously af-
fecting human health and threatening human life. World 
Health Organization (WHO) estimated that the number of 
deaths from cancer worldwide will exceed 13 million in 
2030 (http://www.who.int/mediacentre/factsheets/fs297/en/ 
index.html). How to optimize the therapy for curing cancers 
has become an urgent problem to be solved. The chemo-
therapy is an important treatment option for patients with 
cancer. One of the major hurdles for successful chemother-
apy is the eventual development of multidrug resistance 
(MDR). MDR, which can be intrinsic or acquired, is the 
phenomenon whereby exposure to one drug induces cross- 
resistance to a variety of agents to which the cell has not 
been exposed [1]. The main mechanisms involved in tumor 
MDR contain increased drug efflux, decreased drug influx, 
activation of detoxifying systems (cytochrome P450), acti-
vation of DNA repair and blocked apoptosis (e.g. decreased 
ceramide levels) [2]. Overexpression of ATP-binding cas-
sette (ABC) transporters, including MDR1 (ABCB1), MRP1 
(ABCC1) and ABCG2, was considered as the most com-
mon form. Detailed informantion about MDR has been ex-
pounded in some literature [3,4]. 
A promising strategy to overcome MDR is to use RNA 
interference (RNAi) to selectively silence various onco-
genes, turning off some related molecular pathways. RNAi 
is a sequence-specific and post-transcriptional gene silenc-
ing mechanism, in which small interfering RNA (siRNA) 
molecules (about 20–25 base pairs long) are involved [5]. 
Upon entry of double-stranded siRNA molecules into cells, 
the siRNA is activated through binding to an RNA-induced 
silencing complex (RISC), which unwinds the siRNA du-
plex and produces a single-stranded RNA targeted to com-
plementary messenger RNA (mRNA) and finally the tar-
geted mRNA is cleaved and destroyed [6,7]. Most of studies 
has shown that MDR phenotype is able to be reversed suc-
cessfully with the help of RNAi. However, naked siRNA 
molecules usually have poor transfection efficiency, espe-
cially in vivo, due to its poor stability, low cellular uptake, 
and rapid clearance from the circulation [8]. Therefore, 
siRNA carriers, which can protect siRNA from degradation, 
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deliver it to targeted tumor cells, increase its cellular uptake 
and finally silence the expression of targeted genes, are in 
urgent need.  
Comparing with traditional viral carriers, non-viral ones 
are safer and have minimal immunogenicity. They are easy 
to be prepared on a large scale and at low cost [9,10]. Ad-
vances in nanotechnology open up unprecedented opportu-
nities for obtaining excellent non-viral carriers. Nanocarri-
ers such as liposomes, various kinds of cationic polymers, 
and inorganic materials have been developed to deliver 
siRNA and show good results in reversing MDR. This re-
view mainly summarized recent progress in the designing of 
the siRNA delivery systems (SDS) and their applications to 
overcome tumor MDR. 
1  Barriers in siRNA delivery 
SDS is usually administrated intravenously or intraperitone-
ally in the treatment of multidrug resistant cancer [11]. For 
successful silence of targeted genes, there are mainly three 
barriers needing overcoming: stability in the blood circula-
tion, uptake by targeted tumor cells and the arrival of siR-
NA in cytoplasm (Figure 1). 
Firstly, nanocarriers should protect siRNA from degrada-
tion by nucleases and clearance by the reticuloendothelial 
system (RES) and avoid immune system recognition in the 
blood circulation [12]. The surface charge of the carrier is 
very important [13,14]. Cationic siRNA complexes could 
interact with negatively charged serum proteins such as se-
rum albumin, lipoproteins or IgG proteins by non-specific 
electrostatic attraction, leading to increased size of the com-
plexes and less siRNA accumulation in the targeted site. 
Appropriate long circulation time, which can be realized by 
surface modifications of neutral hydrophilic polymers such 
as PEG, is desired in order to make full use of the enhanced 
permeability and retention effect (EPR). Secondly, after the 
SDS reached the targeted tissues, they are needed to be in-
ternalized by the targeted tumor cells. SDS can enter the 
cells by endocytosis pathway, and this process is influenced 
by the size and composition of the delivery system [15,16]. 
Modification by ligands, small molecule inhibitors, peptides 
and/or antibodies can be utilized to promote the entrance of 
SDS into tumor cells [17–20]. Finally, the complexes are 
usually transported to early endosomes with low pH envi-
ronment after endocytosis. Then the early endosomes grad-
ually evolved into a more acidic late endosomes and finally 
fused with lysosomes [21]. Complete siRNA with biological 
activity should be reserved in this process. The SDS or 
siRNA released from the vectors should have the ability to 
escape from endo/lysosomes and reach the intracellular tar-
geted site, and siRNA must be freed into the cytoplasm 
timely. Only fully dissociated siRNA can form RISC and 
destroy the targeted mRNA. pH or reduction responsive 
materials can be utilized as siRNA carriers to improve this 
process. In a word, the ideal carriers should protect siRNA 
from various adverse factors that may damage the biological 
activities of siRNA in the previous procedures and release 
siRNA into cytoplasm in time.  
2  Nanocarriers for siRNA 
2.1  Liposomes 
Among nonviral carriers, liposome is one of the most prom-
ising candidates for siRNA delivery [22]. Liposomes used  
 
Figure 1  Three barriers in siRNA delivery. (a) Stability in the blood circulation; (b) uptake by targeted tumor cells via endocytosis pathway; (c) arrival of 
siRNA in cytoplasm.
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as siRNA vectors are different from the traditional ones 
with negative surface charge. Phospholipid that constitutes 
them usually contains different types of amine groups. In 
the formulations, these amino groups will carry positive 
charges after protonated. So they can form stable complexes 
with negatively charged siRNA through electrostatic inter-
action and deliver siRNA to targeted tissues or cells. 
Cationic liposomes have been widely investigated. Sev-
eral cationic lipids have been applied for siRNA interfer-
ence, e.g. 1,2-dioleoyl-3-trimethylammonium-propane, N-[1- 
(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl-ammonium methyl 
sulphate and 3-[N-(N,N-dimethylaminoethane)-carbamoyl] 
cholesterol. Saad et al. [23] developed the cationic liposome 
that can co-deliver doxorubicin (Dox), siRNA targeting 
MRP1 mRNA as a suppressor of drug-efflux pumps and 
siRNA targeting Bcl2 mRNA as a suppressor of cellular 
anti-apoptotic defense (Figure 2). It increased the efficacy 
of Dox against multidrug resistant lung cancer cells by two 
different ways and achieved a synergy effect. In the study of 
Chen et al. [24], a multifunctional cationic liposome loaded 
with vascular endothelial growth factor (VEGF) siRNA and 
Dox was formed with a guanidinium-containing cationic 
lipid. With the help of guanidinium it can induce reactive 
oxygen species to inhibit the activity and expression of 
MDR transpoters. A synergistic effect was achieved with 
VEGF siRNA to overcome MDR. However, rapid clearance 
from the circulation and nonspecificity of cationic lipo-
somes limited their in vivo applications. Some modified 
cationic liposomes were developed to address these prob-
lems. Polyethylene glycol (PEG)-coated Bcl2 siRNA-lipo-     
plex was prepared by Nakamura et al. [25] to downregulate 
Bcl2 expression in the 5-Fluorouracil (5-FU) resistant DLD-1 
cell line. Combined with treatment of S-1, an oral formula-
tion of Tegafur, a prodrug of 5-FU, it showed superior tu-
mor growth suppression effect in the DLD-1 xenograft 
model than any single treatment. Modification with PEG 
prolonged circulation time of the lipoplex, decreased its 
immune stimulation and enhanced cellular uptake of the 
siRNA. Jiang et al. [26] developed a RGD peptide (argi-
nine-glycine-aspartic acid)-modified cationic liposomes to 
specially deliver MDR1 siRNA to tumor cells. The RGD 
peptide could bind with integrin receptors, which were over-       
 
Figure 2  Cationic liposome co-delivering Dox, MRP1siRNA and Bcl2-     
siRNA.  
expressed on tumor cells, therefore increasing the accumu-
lation of liposomes in tumors. The MDR1 siRNA complex-
es reversed MDR and significantly enhanced the effect of 
Dox in a mouse model of drug-resistant MCF7/ADR tumor 
by downregulating the expression of P-glycoprotein (P-gp) 
in tumor cells. 
Compared with cationic liposomes, neutral liposomes, 
which are usually formed by 1,2-dioleoyl-sn-glycero-3-phos-    
phatidylcholine (DOPC), usually present much lower cyto-
toxicity. Halder et al. [27] developed a neutral liposomal 
system to deliver Focal adhesion kinase (FAK) siRNA. 
FAK plays an important role in tumor growth and is predic-
tive of poor clinical outcome in ovarian cancer. The com-
plex is highly effective for down-regulating FAK expres-
sion in chemotherapy-resistant HeyA8MDR and A2780- 
CP20 nude mice models. Combined with its treatment, the 
effect of docetaxel or cisplatin on chemotherapy-resistant 
tumors was enhanced by both direct and indirect antiangio-
genic effects. 
2.2  Cationic polymers 
Cationic polymers receive much attention due to their good 
stability, simple preparation and easily modified chemical 
structures [28]. There have been several kinds of cationic 
polymers reported to deliver siRNA, such as poly (ethylene 
imine) (PEI), poly (amido amine) (PAMAM), polyamino 
acid (PAA), poly (-amino esters) (PAE), chitosan and so 
on. 
(1) PEI.  PEI is one of the most extensively investigated 
non-viral vectors [29]. The high content of amino groups in 
PEI enables itself to condense negatively charged siRNA 
firmly. PEI can exert proton sponge effect in the endosomes 
and release the intact siRNA into cytosol where it can initi-
ate the RNA interference pathway [30]. Branched PEI 25 
(kDa) has been considered the “golden” standard of non- 
viral gene delivery system because of its high transfection 
efficacy [31]. A common problem with PEI is its severe 
cytotoxicity and poor compatibility [32–34]. The strong 
positive surface charge of PEI is considered to be the main 
factor associated toxicity. It has been shown that the toxicity 
of PEI is strongly correlated with its molecular weight (MW) 
as well as its structure (branched or linear) [35]. Low-  
molecular-weight PEI (<5 kDa) usually show acceptable 
toxicity. But their efficiency to deliver siRNA is poor. As a 
result, synthesis of a modified PEI with low cytotoxicity 
and enhanced RNAi efficiency has become the recent re-
search focus. 
A lipid-substituted low molecular weight (2 kDa) PEI 
was reported by Aliabadi et al. [36] to deliver breast cancer 
resistance protein (BCRP) siRNA. The complexes consti-
tuted by BCRP siRNA and lipid-substituted PEI down-  
regulate BCRP expression and sensitize the drug-resistant 
cells to chemotherapy drug mitoxantrone, a substrate of 
BCRP, by a 14-fold decrease in the IC50 value. Xue and 
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Wong [37] developed a solid lipid PEI hybrid nanocarrier to 
deliver survivin-targeting siRNA (Figure 3(a)). Knockdown 
of survivin contributed to sensitize drug-resistant cancers to 
chemotherapy compound. This hybrid nanocarrier was can-
cer-specific by coating with folate ligand and realized sus-
tained intracellular siRNA release. An extended RNAi ef-
fect was observed in in vivo experiment. In Xue and Wong’s 
[38] work, PEI hybrid nanocarriers decorated with apolipo-
protein E, a ligand targeting the surface endocytotic recep-
tor megalin, were developed for specific delivering clusterin 
siRNA, which enhanced the transfection specificity of PEI. 
Knockdown of clusterin improved chemosensitization to 
subsequent paclitaxel treatment. Besides lipid, phospholipid 
was also used to improve the RNAi efficacy of PEI. Navarro  
 
Figure 3  Cationic polymers for siRNA delivery. (a) Solid lipid PEI hybrid nanocarrier. siRNA molecules (red wavy curves) complexed with linear PEI 
molecules modified with hydrophobic groups (blue lines with short black branches) are physically encapsulated into nanocarrier core consisting mostly of 
solid lipids (pale yellow). The green surface groups represent targeting moieties (e.g. folate tagged phospholipids). Adapted with permission from [37]. Cop-
yright (2011) American Chemical Society. (b) HA-PAMAM. Adapted with permission from [44]. Copyright (2012) Elsevier. (c) Palmitic acid-modified PLL. 
(d) PAE used for the preparation of PEO-modified nanoparticles. (e) Chitosan.  
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et al. [39] conjugated PEI 1.8 kDa with dioleoylphosphati-
dylethanolamine (DOPE) for MDR1 siRNA delivery. 
DOPE enhanced the transfection efficacy of low-molecular- 
weight PEI, silenced the P-gp expression, and led to a 2-fold 
increase of Dox uptake. Another method for optimizing PEI 
is employing low-molecular-weight PEI as monomers for 
synthesis of an entirely new cationic polymer. Liu et al. [40] 
synthesized a novel siRNA carrier composed of cationic 
PEI (1.2 kDa), a hydrophilic polymer PEG and a biode-
gradable lipid-based crosslinking moiety to deliver MDR1 
siRNA. Reducing the expression of P-gp significantly in-
creased the chemosensitivity of drug-resistant CD133+ cells 
to paclitaxel.  
(2) PAMAM.  Tomalia [41] originally developed PAM-     
AM dendrimers in 1979. PAMAM dendrimers are tree-like 
macromolecules and have an ethylene diamine core and 
amido amine branches [42]. The terminated groups of half 
generations PAMAMs are carboxyls while the full genera-
tions are amine groups. The terminal amine groups are pro-
tonated to obtain positive charges under physiological con-
ditions and thus the dendrimers can condense nucleic acids 
effectively. At the same time, the high density of surface 
functional groups on PAMAM dendrimers makes itself easy 
to be functionalized with various chemical modifications 
[43]. Han et al. [44] reported a polysaccharide hyaluronic 
acid modified PAMAM (generation 5) (HA-PAMAM) to 
co-deliver Dox and major vault protein (MVP) targeting 
siRNA (Figure 3(b)). As a result of MVP knockdown, in-
tracelluar accumulation of Dox was increased and more 
Dox reached its action target, i.e. nucleus, leading to an en-
hanced cytotoxicity in MCF7/ADR cells. 
(3) PAA. Some amino acids, such as histidine, arginine, 
lysine, contain basic groups in their molecular structures 
which can be protonated. PAAs polymerized via these ami-
no acids have been reported to deliver siRNA and present 
better biocompatibility and lower toxicity than PEIs and 
PAMAM [45]. Poly(L-histidine) (PLH) contains imidazole 
groups and is uncharged at physiological conditions. So 
unmodified PLH can hardly be used to deliver siRNA. 
However, as its acid dissociation constant pKa is about 6.0, 
it will be protonated in endosomes and lysosomes, which is 
beneficial for endosomal escape [46]. In order to utilize this 
property for improved RNAi efficiency, some modified 
PLHs, for example, methylated PLH have been developed 
[47]. Arginine consists of a complex guanidinium group 
with a pKa 12.5. Poly(L-arginine) (PLA) can carry positive 
charges in neutral, and even basic environments. Moreover, 
PLA has similar characteristics as membrane-penetrating 
peptide and this is in favor of delivering macromolecules 
across the membrane [48,49]. Many delivery systems based 
on PLA have been developed to deliver siRNA [50–55]. 
However, the PAAs above have seldom been applied as 
siRNA carriers for reversing MDR. Poly(L-lysine) (PLL) is 
one of the most widely studied PAAs for nucleic acid deliv-
ery. It is synthesized via polymerization of N-carboxy-  
anhydride of lysine [56]. PLL contains a large number of 
primary amino groups and could accept hydrogen ions un-
der physiological conditions. Lipid modification of PLL are 
beneficial for the stability of loaded siRNA and the interac-
tion between delivery system and cell membranes, which 
contribute to enhanced transport of loaded siRNA or DNA. 
Abbasi et al. [57] employed palmitic-acid substituted poly 
(L-lysine) as carrier for MDR1 siRNA (Figure 3(c)). Effi-
cient siRNA delivery was observed in both wild type and 
P-gp-overexpressing phenotype cell lines. It resulted in ap-
proximately 40% to 50% P-gp suppression (based on the 
average expression level of the protein) and an approxi-
mately 3-fold increased Dox uptake. It increased cytotoxi-
city of both Dox and paclitaxel in P-gp-overexpressing 
MDA435/LCC6 cells. 
(4) PAE.  PAE is a kind of cationic polymers synthe-
sized via Michael addition reactions between compounds 
containing primary amine or secondary amine and diacry-
lates and is a promising non-viral gene delivery system. 
PAE is able to condense DNA or siRNA into stable nano-
particles at physiological pH. Hydrolytic cleavable ester 
groups in its chemical structure make PAE biodegradable 
and show lower cytotoxicity when compared with some 
other cationic polymers. An ideal PAE can be designed by 
means of changing the monomer of polymer. Zugates et al. 
[58–61] established a library of PAEs which have diverse 
compositions and structures and characterized them through 
high-throughput screening methods. Our laboratory [62,63] 
synthesized a series of bioreducible PAEs, which contains 
disulfide bonds in its structure. Bioreducible PAEs could 
response to the tumor cells' intracellular reducing environ-
ment and realize prompt RNA release. Poly (ethylene oxide) 
(PEO)-modified PAE nanoparticles were prepared by 
Yadav et al. [64] to efficiently encapsulate MDR1 siRNA 
(Figure 3(d)). PEO-modified poly(epsilon-caprolactone) 
(PEO-PCL) nanoparticles loaded with paclitaxel were also 
prepared. The siRNA complexes could down-regulate the 
P-gp expression in multidrug resistant SKOV3TR human 
ovarian adenocarcinoma cells, contributing to increased 
intracellular paclitaxel accumulation and enhanced the cy-
totoxicity of paclitaxel nanoparticles to SKOV3TR cells. 
(5) Chitosan.  Chitosan, a deacetylation derivative of 
chitin, is a natural linear alkaline polysaccharide (Figure 
3(e)). It is a particularly attractive cationic polymer for bi-
omedical applications due to its good biocompatibility, bi-
odegradability, negligible immunogenicity, and low toxicity 
[65,66]. The primary amine groups in repeated glucosamine 
unit of chitosan can be protonated under acidic conditions. 
Therefore chitosan can be utilized as siRNA carriers for 
RNAi. Ziebarth et al. [67] deliver endoglin (CD105) siRNA 
by its chitosan complexes in MDR ES2 and HeyA8 mouse 
models. Chitosan-encapsulated siRNA promoted the apop-
tosis of tumor cells and improves their sensitivity against 
platinum. The in vivo experiment results showed that tumor 
weights of endoglin siRNA treatment group were reduced 
4026 Meng Q S, et al.   Chin Sci Bull   November (2013) Vol.58 No.33 
by 35%-41% compared with control and the endoglin siRNA 
combined with carboplatin group were even better (58%– 
62%). Steg et al. [68] used chitosan nanoparticles to deliver 
Jagged1 siRNA in IGROV-AF1 and taxane-resistant 
SKOV3TRip2 mouse models. The complexes efficiently 
down-regulated the expression of Jagged1 and sensitized 
SKOV3TRip2 tumors to docetaxel. Combination of Jagged1 
siRNA complexes and docetaxel reduced tumor weight by 
87.5%–93.1%. Microvessel density in tumor was reduced 
and the proliferation of tumor cells was inhibited. The au-
thor pointed that Jagged1 down-regulation might sensitize 
tumor cells to taxanes by cross-talk with the GLI2 mediator 
of the Hedgehog pathway rather than through reduction in 
MDR1 expression. In Jagani et al.’s [69] work, chitosan 
nanoparticles were prepared via ionic gelation of chitosan 
by tripolyphosphate for delivery of Bcl2 siRNA in HeLa 
cell and mouse models. Blocking the expression of Bcl2 
gene by the chitosan nanoparticles increased the apoptosis 
rate of tumor cells, enhanced the chemosensitivity to cispla-
tin and significantly reduced the tumor volumes in vivo. 
(6) Cationic polymers synthesized by Reversible Addi-
tion-Fragmentation Chain Transfer (RAFT) Polymerization. 
RAFT polymerization, which was first reported by the Aus-
tralian CSIRO group, is particularly promising as a means 
for designing and synthesizing novel polymers as nuclear 
acid drug vectors [70,71]. It is a robust method by which 
one can control the molecular weight, composition, archi-
tecture and functionality of the polymers. RAFT polymeri-
zation does not need metal catalysts and can be done in 
various ranges of reaction conditions [72]. Some monomers 
without reactive groups (such as hydroxyl groups, carboxyl 
groups, amino groups) can also be polymerized via this 
method. RAFT process contains a chain transfer agent with 
a thiocarbonylthio group, which participates in the follow-
ing formation of intermediate radical species and is an im-
portant factor for successful polymerization [73,74]. Cati-
onic polymers synthesized by RAFT have been reported as 
siRNA carriers to overcome MDR in cancer. Benoit et al. 
[75] prepared a cationic micelle formed from diblock co-
polymers of dimethylaminoethyl methacrylate (pDMAEMA) 
and butyl methacrylate. pDMAEMA contained tertiary amine 
groups and carried positive charges under physiological con-
ditions. It endowed the micelles with the ability to deliver 
polo-like Kinase 1 (plk1) siRNA. In order to enhance cyto-
solic delivery through endosomal release, pH-responsive 
copolymer of poly(styrene-alt-maleic anhydride) was elec-
trostatically complexed with the positively charged siRNA/ 
micelle to form a ternary complex. Treatment with the ter-
nary complexes reduced plk1 gene expression by 50% in 
both the drug-resistant NCI/ADR-RES cell line and the drug- 
sensitive OVCAR8 cell line. It resulted in the sensitization of 
NCI/ADR-RES cells to doxorubicin. The author demon-
strated that this phenomenon is related to p53 signaling 
pathway. Micelles co-delivering plk1 siRNA and Dox re-
sulted in a synergistic effect and sensitize MDR cells to Dox. 
2.3  Inorganic carriers 
Inorganic nanoparticles are attracting more and more inter-
est as siRNA or drug carriers because they are easy to be 
prepared with a defined and stable structures and sizes. 
Various kinds of inorganic materials, such as porous silica 
nanoparticles, gold nanoparticles, nanorods and carbonate 
apatite nanoparticles, have been investigated for delivering 
genes or theraputic agents. 
(1) Porous silicon nanoparticles.  Porous silicon nano-
particles have been considered as excellent candidates for 
medical applications due to their remarkably large surface 
area and biocompatibility [76–78]. They can be endowed 
with more functions via decorating them with various kinds 
of organic polymers. Meng et al. [79] prepared mesoporous 
silicon nanoparticles functionalized by phosphonate groups, 
which allowed electrostatic binding of Dox to the porous 
interior (Figure 4(a)). With the help of phosphonate groups, 
the nanoparticle was then coated with branched PEI. The 
two modifications made it possible to co-deliver Dox and 
MDR1 siRNA to drug-resistant cancer cell line KB-V1 cells. 
The co-delivery system increased the intracelluar and intra-
nuclear Dox concentration to levels exceeding that of free 
Dox or the mesoporous silicon nanoparticles loading Dox 
alone and it improved the sensitivity of the drug-resistant 
cells to Dox. Recently, the same group [80] prepared a PEI- 
PEG copolymer functionalized mesoporous silica nanopar-
ticle to overcome Dox resistance in a multidrug resistant 
human breast cancer xenograft by co-delivering Dox and 
MDR1 siRNA. The siRNA was selected by high throughput 
screening method in MCF7/MDR cells. The co-delivery 
system resulted in stronger inhibition of tumor growth in a 
MDR tumor xenograft model in vivo than free Dox or the 
nanoparticles loaded with either drug or siRNA alone. The 
researchers also analyzed the impact of heterogeneity in the 
tumor microenvironment on the efficacy of siRNA delivery 
in vivo and proposed that the delivery system could be fur-
ther improved by addressing intratumor uneven distribution. 
Mesoporous silicon nanoparticles modified with PAMAM 
dendrimers (generation 2) was investigated by Chen et al. [81] 
for co-delivering Dox and Bcl2 siRNA into multidrug re-
sistant cancer cells. Silicon nanoparticles firstly reacted with 
3-iso-cyanatopropyltriethoxysilane to yield isocyanatopro-
pyl-modified surface and then were linked to PAMAM 
dendrimers (generation 2). This delivery system increased 
the anticancer efficacy of Dox by 132 times in drug resistant 
A2780/AD ovarian cancer cells compared to free Dox be-
cause of the synergistic effect of the Dox and Bcl2 siRNA. 
(2) Gold nanoparticles (AuNPs).  AuNPs have been 
widely investigated for their good bioinertia, lower toxicity, 
ready synthesis, and easy functionalization [82]. Han et al. 
[83] constructed a pH-sensitive gold nanoparicle coated 
with chitosan, PEI and PAH-Cit as a gene vehicle using a 
layer-by-layer assembly method (Figure 4(b)). First, the 
AuNPs were stabilized by chitosan, forming a positively  
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Figure 4  Inorganic nanocarriers for siRNA delivery. (a) Mesoporous silicon nanoparticle modified with branched PEI. (b) Assembly steps for siRNA/ 
PEI/PAH-Cit/AuNP-CS complexes and pH-responsive release of siRNA. Adapted with permission from [78]. Copyright (2012) American Chemical Society.  
charged AuNP-CS core. Then the charge-reversible PAH- 
Cit and PEI were deposited onto the surface of AuNP-CS 
through electrostatic interaction. PEI/PAH-Cit/AuNP-CS 
loaded with siRNA showed 79% siRNA release in 4 h at pH 
5.5 in vitro, suggesting a pH-induced charge-reversing ac-
tion of PAH-Cit. This mechanism also worked in vivo and 
facilitated the escape of siRNA from endosomes. The au-
thor used P-gp targeted siRNA/PEI/PAH-Cit/AuNP-CS to 
knockdown the expression of MDR1 gene in drug-resistant 
MCF7 cells and consequently increased uptake of Dox was 
observed. 
(3) Apatite nanoparticles.  Apatite is a general term for 
phosphate minerals, mainly referring to fluorapatite, hy-
droxylapatite, carbonate apatite, and chlorapatite. It has 
been used as materials for orthopedic and dental applica-
tions because of their resemblance to body hard tissue 
components and good biodegradability and biocompatibility 
[84,85]. Apatite nanoparticles can also serve as efficient 
nuclear acid drugs carriers for RNAi. siRNA or shRNA 
could be loaded in apatite nanoparticles by the method of 
calcium-phosphate coprecipitation. In the process of co-
precipitation, divalent calcium ions can form ionic com-
plexes with the phosphates of nuclear acid. Then the siRNA 
or shRNA was immobilized in calcium phosphate layers 
and was protected from external damage before reaching the 
target site [86]. Li et al. [87] developed pH-sensitive car-
bonate apatite nanoparticles, which were able to co-deliver 
two kinds of siRNA targeting MDR1 and ABCG2 to MCF7 
cells. Carbonate apatite nanoparticles showed high affinity 
interactions with siRNA, facilitating transportation of siR-
NA across the cell membrane. Delivery of single siRNA 
targeting either ABCG2 or MDR1 transporter with car-
bonate apatite nanoparticles demonstrated only about 20% 
enhancement in sensitivity to cisplatin, paclitaxel, or Dox in 
MCF7 cells, while co-delivery of siRNA targeting MDR1 
and ABCG2 to MCF7 cells increased the chemosensitivity 
by about 47%, indicating the reversal of ABC transporter- 
mediated multidrug resistance. 
2.4  Other nanocarriers 
Some polymers, such as -cyclodextrin, PEO-block-poly (- 
caprolactone) (PCL) and dextran, which do not contain 
amino groups in their chemical structures, can also deliver 
siRNA after appropriate modification [88–92]. Li et al. [88] 
developed a MDR1 siRNA and Dox co-delivery system, in 
which CdSe/ZnSe quantum dots were coated with -cycl-     
odextrin via amino acids L-Arg or L-His. The -cyclodextrin 
was used to encapsulate Dox and the linkers L-Arg or L-His 
bound with siRNA to form stable complexes. The delivery 
system co-localized MDR1 siRNA and Dox in drug re-
sistant HeLa/Dox cells and generated synergistic effects of 
the chemotherapeutic and gene therapy agents, leading to 
reduced levels of MDR1 gene expression, enhanced intra-
cellular Dox accumulation and an increased potency of Dox 
to induce apoptosis in HeLa/Dox cells. PCL is one kind of 
the FDA-approved biomaterials. The PCL derivative with 
reactive carboxyl groups, poly (-carboxyl--caprolactone) 
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(PCCL) can be obtained by replacement of the monomer 
-caprolactone with -benzyl carboxylate--caprolactone in 
PCL polymerization. With the help of -carboxyl groups, 
one can endow the PCL polymer with more functionality, 
including the abilities to deliver nuclear acid drug. Xiong  
et al. [89,90] modified PEO-PCCL with spermine or N,N- 
dimethyldipropylenetriamine. Amino groups introduced in 
its structures bound siRNA stably via electrostatic attraction 
under physiological conditions. The PEO blocks were able 
to be decorated with integrin v3 targeting peptide (RGD4C) 
and/or cell penetrating peptide (TAT), increasing the speci-
ficity to MDR cancer cells. Dox was further conjugated to 
PEO-PCCL via pH-sensitive hydrazone bond forming a co- 
delivery system of Dox and MDR1 siRNA [90]. This sys-
tem significantly increased cellular uptake, improved Dox 
penetration into nuclei, and finally enhanced Dox cytotoxi-
city in Dox-resistant MDA-MB-435 cancer models. Dextran 
can be modified with various kinds of functional groups 
easily due to its plentiful reactive hydroxyl groups. A lipid- 
modified dextran-based polymeric nanoparticles, containing 
dextran thiol, dextran stearylamine, and PEG-thiol were 
reported to deliver MDR1 siRNA by Susa et al. [91]. The 
siRNA complexes could efficiently suppress P-gp expres-
sion in the drug resistant osteosarcoma cell lines (KHOSR2 
and U-2OSR2) and re-sensitize these cancer cells to Dox. A 
similar lipid-modified dextran nanosystem, in which dex-
tran stearylamine was replaced by dextran octylamine, was 
also assessed to deliver MDR1 siRNA by their group [92].  
Nanogels, which have been widely used in drug delivery 
and medical diagnosis, can also deliver siRNA to targeted 
cells [93]. Nanogels are able to be loaded with siRNA via 
“breathing-in” manner besides electrostatic attraction [94]. 
Dickerson et al. [95] investigated core/shell nanogels com-
posed of poly (N-isopropylmethacrylamide) (pNIPMAm) 
cross-linked with N,N′-methylene(bisacrylamide) to deliver 
siRNA targeting epidermal growth factor receptor (EGFR). 
Knockdown of (EGFR) contributes to the overcoming of 
MDR in cancer cells [96]. The surface of the nanogels were 
functionalized with peptides (YSA) that specially target 
erythropoietin-producing hepatocellular (Eph)A2 receptor, 
which is up-regulated in vasculature of human tumors. The 
SDS decreased EGFR expression in Hey cells, with the 
highest RNAi efficiency occurring at 48 h and significantly 
increased the sensitivity of this cell line to docetaxel. It is 
worth noting that the specificity of this delivery system was 
confirmed by the experiment of failed reduction of EGFR 
levels in (Eph)A2 negative SK-OV-3 cells. 
3  Conclusion and future direction 
Various kinds of nanocarriers have been developed for de-
livering siRNA in order to overcome tumor MDR in recent 
years. ABC transporters were chosen as the targets in most 
studies. However, mechanisms involved in MDR in tumors 
are very complicated. The generation of MDR phenotype is 
usually a collective result of several mechanisms. Designing 
a nanocarrier that can co-deliver several kinds of siRNA 
against different mechanisms may be one of the solutions to 
overcome MDR. More and more knowledge of cancer bi-
ology and MDR is revealed and more opportunities are 
opened up for reversing MDR. At the same time, with the 
development of material sciences, especially biodegradable 
polymer materials, more well-designed and complicated 
nanocarriers can be synthesized, which increased the possi-
bility of successful treatment to cancer. 
It is worth noting that there have been few siRNA com-
plexes for systemic administration entering clinical trials 
[97]. One of the solutions to improve this situation is in-
creasing the specificity of siRNA nanocarriers to targeted 
tumor cells and decreasing cytotoxicity to normal cells by 
active targeting or passive targeting. Moreover, the varia-
tions of the physicochemical and biological properties of the 
SDS during their in vivo process still need exploring. And 
the approaches to prepare siRNA complexes should be op-
timized for quality assurance of products. 
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